Australia markets closed

Heron Therapeutics, Inc. (HRTX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.9300-0.0100 (-0.34%)
As of 02:56PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 441.97M
Enterprise value 541.19M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)3.20
Price/book (mrq)12.60
Enterprise value/revenue 4.26
Enterprise value/EBITDA -5.21

Trading information

Stock price history

Beta (5Y monthly) 1.71
52-week change 37.69%
S&P500 52-week change 325.65%
52-week high 33.2200
52-week low 30.5000
50-day moving average 32.6756
200-day moving average 31.7074

Share statistics

Avg vol (3-month) 32.65M
Avg vol (10-day) 31.14M
Shares outstanding 5150.33M
Implied shares outstanding 6150.33M
Float 8122.02M
% held by insiders 10.93%
% held by institutions 176.07%
Shares short (28 Mar 2024) 425.55M
Short ratio (28 Mar 2024) 49.17
Short % of float (28 Mar 2024) 419.57%
Short % of shares outstanding (28 Mar 2024) 417.00%
Shares short (prior month 29 Feb 2024) 424.53M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:20
Last split date 313 Jan 2014

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023


Profit margin -87.02%
Operating margin (ttm)-28.39%

Management effectiveness

Return on assets (ttm)-24.56%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)127.04M
Revenue per share (ttm)0.92
Quarterly revenue growth (yoy)14.00%
Gross profit (ttm)N/A
EBITDA -90.12M
Net income avi to common (ttm)-110.56M
Diluted EPS (ttm)-0.8000
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)80.41M
Total cash per share (mrq)0.54
Total debt (mrq)179.63M
Total debt/equity (mrq)N/A
Current ratio (mrq)2.37
Book value per share (mrq)-0.23

Cash flow statement

Operating cash flow (ttm)-58.79M
Levered free cash flow (ttm)-16.84M